Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results

被引:16
|
作者
Lambrecht, Marie [1 ,3 ]
Clementel, Enrico [2 ]
Sonke, Jan-Jacob [3 ]
Nestle, Ursula [4 ,5 ]
Adebahr, Sonja [5 ,6 ,7 ]
Guckenberger, Mathias [8 ]
Andratschke, Nicolaus [8 ]
Weber, Damien C. [8 ,9 ]
Verheij, Marcel [3 ]
Hurkmans, Coen W. [1 ]
机构
[1] Catharina Hosp, Dept Radiat Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] EORTC Headquarters, Dept Qual Assurance, Brussels, Belgium
[3] Netherland Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[4] Kliniken Maria Hilf GmbH Monchengladbach, Dept Radiat Oncol, Monchengladbach, Germany
[5] Univ Freiburg, Fac Med, Med Ctr, Dept Radiat Oncol, Freiburg, Germany
[6] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland
[9] Paul Scherrer Inst, ETH Domain, Ctr Proton Therapy, Villigen, Switzerland
关键词
Benchmark; SBRT; Lung; Planning exercise; Clinical trial; RADIATION; ATLAS;
D O I
10.1016/j.radonc.2018.10.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report on the benchmark case (BC) study performed in the context of the European Organisation for Research and Treatment of Cancer prospective multicentre Lungtech trial of SBRT for patients with inoperable centrally located lung tumours. Methods and materials: Target volume and organs at risk (OARs) delineations first needed to be acceptable before the treatment plan was reviewed. Retrospectively, Dice similarity coefficients of the OARs and the target volumes were calculated and a set of gold standard contours adapted for each institution margins was applied on the accepted dose submissions to evaluate the influence of acceptable delineation variations on dosimetry. Results: Twenty-five institutions participated. Five BCs were accepted at the first attempt. Twenty institutions had to revise their delineation at least once and seven had to revise their planning once. The V-60 Gy dose coverage improved significantly (p = 0.05) between the first and final submissions from median (range) 94.8% (22.5-97.8) to 95.3% (70.5-99.3). The median Dice coefficient varied significantly between OARs: The lowest values were found for the brachial plexus 0.25 (0.01-0.54) and the highest for the spinal cord 0.89 (0.71-0.95). The mean PTV Dice coefficient was 0.82 (0.48-0.92). Applying the gold standard contours, only one institution remained compliant with the dose coverage criteria with V-60 Gy median (range) of 83.4% (54.2-93.9). Conclusions: Clinical guidelines and radiotherapy protocols are not a substitute for timely radiotherapy quality assurance procedures, which improve dose coverage significantly. Delineation remains the main source of BC rejection and plan review without first reviewing delineation may not be efficient. Our results show that delineation variations seem to have a larger influence on PTV coverage than variations in planning and irradiation techniques and thus suggest that dose tolerance criteria should preferably take into account the accuracy of delineation. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 50 条
  • [41] Quality assurance review of thoracic radiotherapy in EORTC 08941: A randomized trial of surgery (S) versus thoracic radiotherapy (RT) in patients (pts) with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy (ICT)
    Kramer, G
    van Meerbeeck, J
    van Schil, P
    Uitterhoeve, L
    Smit, E
    Schramel, F
    Biesma, B
    Tjan-Heijnen, V
    Legrand, C
    Splinter, T
    LUNG CANCER, 2005, 49 : S79 - S80
  • [42] Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: Comparison of the results of two individual case reviews performed early and late during the accrual period
    Poortmans, PMP
    Ataman, F
    Davis, JB
    Bartelink, H
    Horiot, JC
    Pierart, M
    Collette, L
    Van Tienhoven, G
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 (03) : 278 - 284
  • [43] Establishment of a virtual multidisciplinary team (vMDT) to provide central review of eligibility for a phase II/III radiotherapy trial assessing stereotactic body radiotherapy (SBRT) in patients with oligoprogressive non-small cell lung cancer (NSCLC)
    Toms, Christy
    Patel, Priyanka
    Kilburn, Lucy
    Alawo, Deborah
    Doran, Simon
    Riddell, Angela
    McDonald, Fiona
    Bliss, Judith
    TRIALS, 2019, 20
  • [44] Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.
    Campbell, Allison M.
    Herbst, Roy S.
    Gettinger, Scott N.
    Goldberg, Sarah B.
    Kluger, Harriet M.
    Chiang, Anne C.
    Lilenbaum, Rogerio
    Schalper, Kurt A.
    Sowell, Ryan T.
    Kaech, Susan M.
    Decker, Roy H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: A quality-assurance report on the dummy run of EORTC phase III randomized trial 22922/10925 in stage I-III breast cancer
    Poortmans, PMP
    Venselaar, JLM
    Struikmans, H
    Hurkmans, CW
    Davis, JB
    Huyskens, D
    van Tienhoven, G
    Vlaun, V
    Lagendijk, JJW
    Mijnheer, BJ
    De Winter, KA
    Van der Hulst, MH
    Van den Bogaert, WFC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (05): : 1399 - 1408
  • [46] Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID)
    Hallqvist, A.
    Koyi, H.
    de Petris, L.
    Lindberg, K.
    Farooqi, S.
    Helland, A.
    Wikstrom, A.
    Johansson, M.
    Planck, M.
    Lindberg, L.
    Yksnoy, O.
    Gronberg, B. H.
    Helbekkmo, N.
    Nyman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S729 - S730
  • [47] A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC)
    Lee, Siow Ming
    Lewanski, Conrad
    Counsell, Nicholas
    Ottensmeier, Christian
    Bates, Andrew T.
    Patel, Nirali
    Wadsworth, Christina
    Ngai, Yenting
    Hackshaw, Allan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S298 - S299
  • [48] Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)
    Samalin, E.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Laurent-Puig, P.
    Ychou, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S418 - S418
  • [49] Chemotherapy-radiotherapy multimodalities with vinorelbine-cisplatin for stage IIIB non small cell lung cancer patients (NSCLC pts): Results from a Morrocan Phase II trial
    Acharki, A
    Jouhadi, H
    Benchakroun, N
    Sahraoui, S
    Tawfiq, N
    Benider, A
    Gasmi, J
    LUNG CANCER, 2005, 49 : S232 - S232
  • [50] Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer
    Timmerman, R. D.
    Hu, C.
    Michalski, J.
    Straube, W.
    Galvin, J.
    Johnstone, D.
    Bradley, J.
    Barriger, R.
    Bezjak, A.
    Videtic, G. M.
    Nedzi, L.
    Werner-Wasik, M.
    Chen, Y.
    Komaki, R. U.
    Choy, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S30 - S30